Researchers at University of California San Diego School of Medicine, Ludwig Institute for Cancer Research and The Scripps Research Institute, with colleagues in Los Angeles and Japan, report that depriving deadly brain cancer cells of cholesterol, which they import from neighboring healthy cells, specifically kills tumor cells and caused tumor regression and prolonged survival in mouse models.

A drug used to treat multiple sclerosis (MS), alemtuzumab, was found to reverse some of the physical disability caused by the disease, according to new research published in the October 12, 2016, online issue of Neurology®, a medical journal of the American Academy of Neurology. Because it can cause serious side effects, alemtuzumab is generally used in people who have not responded well to other MS drugs; however, in this study it was used relatively early in the course of MS.

Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network's Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, have published new findings that challenge current beliefs about how and why pancreatic cancer is so aggressive. This deadly disease often strikes "out of nowhere," and the cancer is often inoperable by the time the patient experiences symptoms.

A key protein that causes heart failure has been revealed through new research from a collaboration based in Kumamoto University, Japan. The protein ANGPTL2 (Angiopoietin-like protein 2) is secreted by cardiac muscle cells and decreases the contraction force of the heart by reducing energy production and the regulating function of the calcium concentration in cardiac muscle cells.

Researchers at Columbia University Medical Center and the Data Science Institute at Columbia University have uncovered a potentially dangerous drug interaction using data science. Their findings were published in the latest issue of the Journal of the American College of Cardiology. Safe when taken on their own, some prescription drugs become deadly when combined. Many of these interactions are well known, but others remain hidden to doctors, drug companies, and patients.

In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage. Studies in mice have shown that boosting the levels of this cell metabolite - known as NAD+ - can produce multiple health benefits,

Connections between industry and clinicians exist and a new study published online by JAMA Dermatology used publicly available data to analyze the nature and extent of industry payments to dermatologists. Marie Leger, M.D., Ph.D., of the Weill Cornell Medicine, New York, and coauthors used the Centers for Medicare and Medicaid Services (CMS) Sunshine Act Open Payment database, which records payments to physicians from manufacturers or group-purchasing organizations that make products reimbursed by a government-run health program.